LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Status:
Completed
Trial end date:
2018-01-17
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study was to determine whether treatment with LEE011
demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic
malignancies to warrant further study.